Equity Profile

TNGX

Tango Therapeutics, Inc.

Health CareBiotechnology$4.3B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

$-0.32

Revenue

Revenue figures are crucial for understanding the company's sales performance and market traction.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as new treatments and technologies emerge to address complex diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1-2026, Tango Therapeutics reported an EPS of $-0.32, matching analyst expectations with a slight negative surprise. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Tango to report a loss of $-0.32 per share this quarter, with no revenue anticipated. The market will be closely watching for any updates on product development or partnerships.

Bull Case

If Tango can demonstrate progress in its drug pipeline or announce new collaborations, it could lead to a positive market reaction and potentially higher stock prices.

Bear Case

Conversely, if the company fails to provide any significant updates or reports a larger-than-expected loss, investor sentiment may turn negative, leading to a decline in stock value.

Key Metrics to Watch

EPS

$-0.32

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures are crucial for understanding the company's sales performance and market traction.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug pipeline or clinical trials?

Investors are keen to know about progress in drug development, as this can significantly impact future revenue potential.

What is the outlook for the company's financial performance in the coming quarters?

Guidance on future performance can influence investor confidence and stock valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for positive news on drug development, which could significantly boost investor sentiment.

Supporting Evidence

The options market is pricing a smaller move than the historical average, indicating a potential undervaluation of upcoming volatility.

The recent stock performance suggests that even minor positive news can lead to significant gains.

Key Risk

If any updates on drug development exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the risks of continued losses and uncertainty in the biotech sector.

Bull Confirmed If

Any positive news regarding drug development or partnerships could lead to a significant stock price increase.

Bear Confirmed If

A larger-than-expected loss or lack of updates on the drug pipeline could confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±13.96%

Pricing cheap

The options market is pricing in an expected move of about 8.57% following the earnings report, suggesting that traders anticipate some volatility.

Options are pricing a smaller move than the historical average, indicating a potentially undervalued setup.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations with a smaller loss and provides positive updates, history suggests the stock could rise by around 0.09%.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react moderately, reflecting uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of around 5.68% in stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Any new partnerships or collaborations that could enhance growth prospects.
3Management's outlook on future financial performance and market conditions.
4Details on cost management strategies and operational efficiency.
5Responses to analyst questions regarding competitive positioning in the biotech space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

$-0.32

Revenue

Revenue figures are crucial for understanding the company's sales performance and market traction.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1-2026, Tango Therapeutics reported an EPS of $-0.32, matching analyst expectations with a slight negative surprise. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Tango to report a loss of $-0.32 per share this quarter, with no revenue anticipated. The market will be closely watching for any updates on product development or partnerships.

Bull Case

If Tango can demonstrate progress in its drug pipeline or announce new collaborations, it could lead to a positive market reaction and potentially higher stock prices.

Bear Case

Conversely, if the company fails to provide any significant updates or reports a larger-than-expected loss, investor sentiment may turn negative, leading to a decline in stock value.

Key Metrics to Watch

EPS

$-0.32

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures are crucial for understanding the company's sales performance and market traction.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug pipeline or clinical trials?

Investors are keen to know about progress in drug development, as this can significantly impact future revenue potential.

What is the outlook for the company's financial performance in the coming quarters?

Guidance on future performance can influence investor confidence and stock valuation.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for positive news on drug development, which could significantly boost investor sentiment.

Supporting Evidence

The options market is pricing a smaller move than the historical average, indicating a potential undervaluation of upcoming volatility.

The recent stock performance suggests that even minor positive news can lead to significant gains.

Key Risk

If any updates on drug development exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the risks of continued losses and uncertainty in the biotech sector.

Bull Confirmed If

Any positive news regarding drug development or partnerships could lead to a significant stock price increase.

Bear Confirmed If

A larger-than-expected loss or lack of updates on the drug pipeline could confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±13.96%

Pricing cheap

The options market is pricing in an expected move of about 8.57% following the earnings report, suggesting that traders anticipate some volatility.

Options are pricing a smaller move than the historical average, indicating a potentially undervalued setup.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations with a smaller loss and provides positive updates, history suggests the stock could rise by around 0.09%.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react moderately, reflecting uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of around 5.68% in stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Any new partnerships or collaborations that could enhance growth prospects.
3Management's outlook on future financial performance and market conditions.
4Details on cost management strategies and operational efficiency.
5Responses to analyst questions regarding competitive positioning in the biotech space.